Is this Moderna envy? Perhaps, but any way you cut it, the news from Pfizer today is all good. Their initial estimate on effectiveness of their COVID-19 vaccine was 90%, but this morning they updated it to the same 95% level as Moderna’s initial estimate.
And unlike Moderna, Pfizer’s ready to start giving vaccinations before the end of the month — if the FDA’s up for a quick approval:
Pfizer on Wednesday said its COVID-19 vaccine was 95 percent effective and had no serious side effects — and that it will be submitted for regulatory approval “within days,” according to reports.
The US drugmaker and its German partner BioNTech announced that their vaccine is even more effective at preventing the disease than what they previously thought — 90 percent — last week, NBC News reported.
After completing their Phase 3 trial, the companies said there have been no serious side effects among the 41,135 adults who received two doses. The most common reactions were that 3.7 percent of them experienced fatigue and 2 percent had a headache, they said.